Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 6,684 matching trials from the live ClinicalTrials.gov search.

Filters: Stanford, California Clear all

Conditions: Leukemia, Leukemia, Myeloid, Monocytic Leukemia
Interventions: Enasidenib mesylat dose escalation; Drug
Lead sponsor: Tian Yi Zhang; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Bipolar Disorder, Panic Disorder, Generalized Anxiety Disorder
Interventions: quetiapine SR, divalproex sodium ER, placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 3
States / cities: Palo Alto, California • Tampa, Florida • Cincinnati, Ohio

Conditions: Pain, Fever
Interventions: IV Acetaminophen; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 29 Days to 16 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: Stanford, California • Ann Arbor, Michigan • Durham, North Carolina + 2 more

Conditions: Heart Failure, Congestive
Interventions: KW-3902IV; Drug
Lead sponsor: NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 10
States / cities: Stanford, California • Washington D.C., District of Columbia • Sarasota, Florida + 7 more

Conditions: Osteosarcoma
Interventions: Biospecimen Collection, Laboratory Biomarker Analysis, Questionnaire Administration; Procedure · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 93
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: Presatovir, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 17
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 14 more

Conditions: Influenza
Interventions: Fluzone®, FluMist®; Biological
Lead sponsor: Stanford University; Other
Eligibility: 6 Months to 49 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Interventions: Ampreloxetine, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 30 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 26
States / cities: Scottsdale, Arizona • Fountain Valley, California • La Jolla, California + 21 more

Conditions: Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma
Interventions: pembrolizumab, gemcitabine, vinorelbine, liposomal doxorubicin, Stem cell mobilization and collection, Involved-site radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 10
States / cities: Duarte, California • Stanford, California • Miami, Florida + 7 more

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 12 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 33
States / cities: Downey, California • Long Beach, California • Los Angeles, California + 18 more

Conditions: Chest--Diseases
Interventions: Traditional workflow triage, Machine learning workflow triage, Random workflow triage; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: Premature Birth
Interventions: Language Treatment, Control Treatment; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 24 Weeks to 31 Weeks
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Stanford, California

Conditions: Acute Myeloid Leukemia (AML) With Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults, AML (Adult) With 11q23 (MLL) Abnormalities, AML (Adult) With Del (5q), AML (Adult) With Inv (16) (p13; q22), AML (Adult) With t (16;16) (p13; q22), AML (Adult) With t (8; 21) (q22; q22), Secondary AML (Adult), Untreated AML (Adult)
Interventions: Decitabine, Midostaurin; Drug
Lead sponsor: David Iberri; Other
Eligibility: 60 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Mycosis Fungoides, Lymphomas: Non-Hodgkin, Lymphomas: Non-Hodgkin Peripheral T-Cell, Lymphomas: Non-Hodgkin Cutaneous Lymphoma
Interventions: Total Skin Electron Beam Therapy (TSEBT); Radiation
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Influenza
Interventions: Quadrivalent inactivated influenza vaccine (IIV); Biological
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Moderately to Severely Active Crohns Disease
Interventions: Afimkibart, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 64
States / cities: Dothan, Alabama • Glendale, Arizona • Lancaster, California + 57 more

Conditions: Ocular Inflammation
Interventions: KPI-121 1%, Prednisolone acetate; Drug
Lead sponsor: Kala Pharmaceuticals, Inc.; Industry
Eligibility: Up to 3 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 4
States / cities: Palo Alto, California • Detroit, Michigan • Erie, Pennsylvania + 1 more

Conditions: Carcinoma, Hepatocellular, Metastatic Liver Cancer
Interventions: BioTraceIO Lite; Device
Lead sponsor: Techsomed Medical Technologies LTD; Industry
Eligibility: 21 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Phoenix, Arizona • Stanford, California • Boston, Massachusetts + 3 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Saquinavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 44
States / cities: Los Angeles, California • Menlo Park, California • San Diego, California + 27 more

Conditions: COVID-19
Interventions: Remdesivir, Standard of Care; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 12 Years and older
Enrollment: 1,113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 106
States / cities: Anaheim, California • Berkeley, California • Burlingame, California + 76 more

Conditions: Macula Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Interventions: Episcleral Celecoxib; Drug
Lead sponsor: Targeted Therapy Technologies, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Arthritis, Rheumatoid
Interventions: CP-690,550, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 795 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 46
States / cities: Huntsville, Alabama • Jonesboro, Arkansas • Palo Alto, California + 41 more

Conditions: Asthma, Chronic Disease
Interventions: Chronic Disease Self-Management Online Workshop; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD

Safety and Pharmacokinetic (PK) Study of Intravenous (IV) Acetaminophen Administration in Pediatric Inpatients

Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).

Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors

Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection

Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

The Safety and Effectiveness of Zidovudine in the Treatment of HIV-Infected Children With Mild to Moderate Symptoms

Clinical Validation of Machine Learning Triage of Chest Radiographs

Listening to Mom 2: Neural, Clinical and Language Outcomes

Comprehensive Screening for Women at High Genetic Risk for Developing Breast Cancer

Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 2 Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides

Response to Influenza Vaccine During Pregnancy

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children

Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications

Healthier Living Canada